February 23 2021
Dr. Douglas Levine, Chair of the NRG Cancer Prevention (CP) Committee, has announced he will step down April 1, 2021 to pursue other opportunities outside of academic medicine. Dr. Levine has served in this leadership role since 2018 and has helped organize the prevention committee expansion. Dr. Levine has also been the lead PI for NRG’s large prevention trial to compare two surgical procedures in women with BRCA1 mutations to assess the risk of ovarian cancer, NRG-CC008 (SOROCk).
Having learned of Dr. Levine’s intent to step down as Chair, we are seeking a candidate to continue this work. The ideal candidate is an investigator with an active program of funded research and publications focused on the NRG cancer prevention priorities of reducing cancer risk through optimal screening, biomarker evaluation and risk reduction strategies such as behavioral modification and chemoprevention. In addition to leading the Cancer Prevention Committee, this candidate will also serve as a co-chair of the Cancer Prevention and Control Committee alongside Dr. Lisa Kachnic. This individual will work closely with Dr. Kachnic on the priorities of the overall committee.
Individuals with interest in the position should send their CV along with a cover letter outlining their vision and how it aligns with the priorities mentioned above by March 12, 2021. Please send all documents or questions regarding this position to Erica Field, NRG NCORP Administrator (fielde@nrgoncology.org).